Enjoy complimentary customisation on priority with our Enterprise License!
The kidney transplantation therapeutics market size is forecast to increase by USD 643.15 million at a CAGR of 4.49% between 2023 and 2028. The market is experiencing significant growth due to the rising prevalence of chronic kidney disease (CKD) and renal impairments worldwide. According to the National Kidney Foundation, over 37 million adults in the US have CKD, and this number is projected to increase. Kidney transplantation is the preferred treatment option for end-stage renal disease, and the number of transplants performed annually is increasing. Novel techniques, such as living donor transplants and desensitization protocols, are gaining popularity and expanding the pool of potential donors and recipients. However, the use of immunosuppressants to prevent rejection poses challenges, including side effects and long-term health risks. Despite these challenges, advancements in immunosuppressive therapies and transplantation techniques are expected to drive market growth.
Kidney transplantation is a therapeutic option for individuals suffering from end-stage renal failure due to chronic kidney disease. This procedure involves replacing a failing kidney with a healthy donor kidney, which can significantly improve patients' quality of life. Donor kidneys can come from living donors or deceased organ donors, and health conditions of both donor and recipient are closely assessed before the transplant. The surgery, which involves removing the diseased kidney and implanting the donor kidney, is followed by postoperative care, including diet and nutrition, hydration, and medications to prevent kidney rejection. The immune system plays a crucial role in the transplant process, and the use of immunosuppressants is essential to prevent antibody formation and ensure a compatible transplant.
However, despite advancements in transplantation techniques, complications such as kidney rejection, high blood pressure, nausea, diarrhea, and edema can occur. Survival rates for kidney transplant recipients are generally higher than those on long-term dialysis, but ongoing care and monitoring by healthcare providers are necessary to manage symptoms and minimize complications. Regular blood tests and monitoring for signs of kidney harm are essential to ensure the long-term success of the transplant.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The selective cytokine inhibitors segment is estimated to grow significantly during the forecast period. Chronic kidney disease and end-stage renal failure necessitate life-saving kidney transplantation for patients. Donor kidneys, sourced from living donors or deceased organ donors, undergo surgery to replace the failing kidney. Post-transplant, the immune system poses a significant challenge due to kidney transplant rejection. Immunosuppressants, such as cyclosporine, tacrolimus, and sirolimus, inhibit the production and function of cytokines, which mediate immune response signals. These drugs, including their branded and generic forms, are crucial in kidney transplantation. Tacrolimus, specifically, is commonly used due to its superior therapeutic efficacy. Post-surgery, patients require meticulous postoperative care, including diet and nutrition, hydration, medications, and symptom management.
Furthermore, symptoms like edema, high blood pressure, nausea, and diarrhea may arise. Immunosuppressants, such as tacrolimus, inhibit antibody formation and ensure a compatible transplant. Regular blood tests monitor kidney function and detect potential complications, such as infection risk, kidney harm, and post-transplant malignancy, including non-melanoma skin cancer. Patients must adhere to medicines, undergo cancer screening, and follow post-transplant care guidelines for optimal outcomes. Monoclonal antibodies may be used to treat allograft rejection and tumor response.
Get a glance at the market share of various segments Request Free Sample
The selective cytokine inhibitors segment was valued at USD 1.03 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is witnessing significant growth due to the high prevalence of kidney diseases, such as chronic kidney disease (CKD) and end-stage renal disease (ESRD). The region's advanced healthcare infrastructure, including specialized transplant centers, nephrology units, and well-equipped hospitals, facilitates efficient kidney transplantation procedures and post-transplant care. North America's leadership in medical research and technological innovation drives the development of new immunosuppressive drugs, diagnostic tools, and surgical techniques, enhancing transplant success rates. Allo-immunity and tumor-associated antigens are key challenges in kidney transplantation. Immunosuppression is crucial to prevent T lymphocyte activation and T cell activation, which can lead to graft rejection. Immune checkpoints and tumoral microenvironments play significant roles in tumor-infiltrating cells and cancer development. The strong pharmaceutical industry in North America is actively involved in the development and commercialization of drugs to address these challenges, further fueling market growth.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rising prevalence of CKD and renal impairments is the key driver of the market. Chronic kidney disease (CKD) affects approximately 8.5-9.5% of the global adult population, with diabetes, hypertension, vascular disease, and glomerulonephritis being major contributing factors. In underdeveloped and developing countries, infections such as those caused by Streptococcus species, hepatitis B and C viruses, and human immunodeficiency virus (HIV) are significant causes of CKD. As the population ages, CKD becomes more prevalent, particularly among those aged 65 years and above. End-stage renal failure (ESRF) due to CKD often necessitates dialysis or kidney transplantation. Donor kidneys can come from living donors or deceased organ donors. Surgery involves removing the diseased kidney and replacing it with a compatible transplant.
Furthermore, postoperative care includes diet and nutrition, hydration, medications, and monitoring for kidney transplant rejection. Immune system compatibility, antibody formation, and blood tests are crucial components of a successful transplant. Medications such as immunosuppressants, antibiotics, and cancer screening are necessary to prevent complications like high blood pressure, nausea, diarrhea, kidney harm, and infection risk. Healthcare providers oversee post-transplant care, ensuring patients adhere to medicines and undergo regular physicals to mitigate the risk of post-transplant malignancy, including non-melanoma skin cancer. Monoclonal antibodies and allograft rejection treatments are used to enhance tumor response.
Novel techniques for kidney transplantation is the upcoming trend in the market. Chronic kidney disease and end-stage renal failure are leading health conditions that necessitate kidney transplantation. This therapeutic approach offers a superior alternative to long-term dialysis, improving patients' quality of life. Kidney transplantation involves the use of donor kidneys, which can come from living donors or deceased organ donors. The surgery, which engages the immune system, requires meticulous postoperative care, including diet and nutrition, hydration, and medications to prevent kidney rejection. Survival rates for kidney transplant recipients are significantly higher than those on dialysis.
However, risks such as kidney harm, infection, and cancer are associated with the procedure. Immunosuppressants are essential medications to prevent allograft rejection and antibody formation. Post-transplant care includes regular physicals, blood tests, and adherence to medications to minimize the risk of post-transplant malignancy, such as non-melanoma skin cancer. Symptoms like high blood pressure, nausea, and diarrhea are common post-transplant, necessitating close monitoring and appropriate interventions. Immunosuppressants also increase the risk of infection, necessitating the use of antibiotics and cancer screening. Patients with diabetes require additional care to manage their condition post-transplant. The healthcare provider plays a crucial role in ensuring successful kidney transplantation and long-term patient care.
The side effects of immunosuppressants is a key challenge affecting the market growth. Chronic kidney disease and end-stage renal failure necessitate life-saving kidney transplantation for affected individuals. Donor kidneys can come from living donors or deceased organ donors, and transplant surgery is a complex procedure with postoperative care requirements. Kidney transplant rejection, triggered by the immune system, is a significant concern. Immunosuppressants, essential medications to prevent rejection, come with side effects. These include diarrhea, increased infection risk, nausea, and vomiting, which impact patients' adherence to treatment.
Furthermore, immunosuppressants can also lead to muscle damage, hyperglycemia, and secondary diabetes. Post-transplant care includes diet and hydration management, blood tests, monitoring for high blood pressure, and cancer screening. Symptoms like edema, nausea, and diarrhea may arise, necessitating antibiotics to manage infections. Long-term complications include post-transplant malignancy, non-melanoma skin cancer, and allograft rejection. Patients must adhere to medicines, undergo regular physicals, and monitor tumor response.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.: The company offers kidney transplantation therapeutics such as 2.0 Synopsis.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Kidney transplantation is a therapeutic option for individuals suffering from end-stage renal failure due to chronic kidney disease. Donor kidneys can come from living donors or deceased organ donors, and the health conditions of both donor and recipient are crucial factors in ensuring a successful transplant. Surgery involves removing the kidney from the donor and implanting it into the recipient. Postoperative care includes diet and nutrition, hydration, medications, and close monitoring for kidney transplant rejection. The immune system plays a significant role in kidney transplantation, as the body may form antibodies against the transplanted kidney. Compatibility tests, such as blood tests, help identify a suitable donor.
Furthermore, immunosuppressants are administered to suppress the immune response and prevent rejection. Post-transplant care includes regular healthcare provider visits, and monitoring for symptoms like edema, high blood pressure, nausea, and diarrhea. Patients are also at risk for infections, cancer, and post-transplant malignancy. Regular cancer screening, antibiotics, and adherence to medications are essential. Allograft rejection and tumor response are significant concerns, and monoclonal antibodies may be used to treat these conditions. Regular physicals and follow-up care are necessary to ensure the best possible outcomes.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
171 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.49% |
|
Market growth 2024-2028 |
USD 643.15 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.05 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 45% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Asahi Kasei Corp., Astellas Pharma Inc., B.Braun SE, Bristol Myers Squibb Co., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius Medical Care AG and Co. KGaA, GlaxoSmithKline Plc, Hansa Biopharma AB, Novartis AG, Organ Recovery Systems Inc., Pfizer Inc., Sanofi SA, Strides Pharma Science Ltd., TFF Pharmaceuticals Inc., TolerogenixX GmbH, TransMedics Inc., and Transonic Systems Inc. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.